Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Adenocarcinoma|Metastatic Triple-Negative Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7
Interventions: DRUG: Binimetinib|OTHER: Laboratory Biomarker Analysis|BIOLOGICAL: Pembrolizumab
Sponsor: Mayo Clinic